Capricor Therapeutics (NASDAQ:CAPR) Stock Breaks Below Two Hundred Day Moving Average – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $18.77 and traded as low as $5.80. Capricor Therapeutics shares last traded at $6.13, with a volume of 2,748,399 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CAPR shares. Alliance Global Partners downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a report on Tuesday, July 28th. B. Riley Financial raised shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $5.00 to $21.00 in a report on Monday, September 14th. Maxim Group cut shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Piper Sandler upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, September 1st. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $30.25.

Capricor Therapeutics Stock Performance

The stock’s fifty day moving average is $8.21 and its two-hundred day moving average is $18.68. The firm has a market cap of $344.77 million, a price-to-earnings ratio of -2.42 and a beta of 0.61.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SBI Securities Co. Ltd. increased its position in Capricor Therapeutics by 834.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 23,495 shares during the period. Activest Wealth Management raised its stake in Capricor Therapeutics by 100.0% during the 3rd quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 2,000 shares in the last quarter. Squarepoint Ops LLC boosted its position in Capricor Therapeutics by 57.8% during the 2nd quarter. Squarepoint Ops LLC now owns 19,731 shares of the biotechnology company’s stock worth $475,000 after acquiring an additional 7,231 shares during the period. Montanova Capital LLC boosted its position in Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after acquiring an additional 274,184 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Capricor Therapeutics during the 2nd quarter worth $3,895,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.